Thalys Medical Technology Group Corporation (SHA:603716)
17.57
+0.46 (2.69%)
Sep 1, 2026, 3:00 PM CST
SHA:603716 Revenue
Thalys Medical Technology Group had revenue of 160.98M CNY in the quarter ending June 30, 2026, a decrease of -45.63%. This brings the company's revenue in the last twelve months to 836.23M, down -41.05% year-over-year. In the year 2025, Thalys Medical Technology Group had annual revenue of 1.08B, down -40.52%.
Revenue (ttm)
836.23M
Revenue Growth
-41.05%
P/S Ratio
4.38
Revenue / Employee
800.22K
Employees
1,045
Market Cap
3.66B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.08B | -733.73M | -40.52% |
| Dec 31, 2024 | 1.81B | -195.45M | -9.74% |
| Dec 31, 2023 | 2.01B | -302.50M | -13.10% |
| Dec 31, 2022 | 2.31B | -290.92M | -11.19% |
| Dec 31, 2021 | 2.60B | 474.08M | 22.30% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Shanghai Runda Medical Technology | 6.72B |
| Maccura Biotechnology Co.Ltd | 2.13B |
| Medicalsystem Biotechnology | 1.63B |
| Beijing Strong Biotechnologies,Inc. | 1.37B |
| Shanghai Labway Clinical Laboratory | 1.28B |
| Amoy Diagnostics | 1.18B |
| Berry Genomics Co.,Ltd | 929.15M |
| SMO ClinPlus CO.,LTD. | 824.77M |